Functional imaging of colorectal cancer: Positron emission tomography, magnetic resonance imaging, and computed tomography

Clinical Colorectal Cancer

Volumn 8, Issue 2, 2009, Pages 77-87

  Kapse, Nikhil ^a   Goh, Vicky ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Carcinoembryonic antigen; Radiotracers; Relaxation rate; Transrectal ultrasound

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' CU 64; 3' FLUOROTHYMIDINE F 18; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; FLUOROIMIDAZOLE F 18; FLUOROURACIL; GADOLINIUM; GALACTO ARGINYLGLYCYLASPARTIC ACID F 18; IODINATED CONTRAST MEDIUM; IODINE; OXALIPLATIN; RADIOPHARMACEUTICAL AGENT; STREPTAVIDIN CU 64; UNCLASSIFIED DRUG; WATER O 15; YTTRIUM 90;

ANGIOGENESIS; BLOOD OXYGENATION; BLOOD VOLUME; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CHEMOEMBOLIZATION; CLINICAL ASSESSMENT; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CRYOABLATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE FREE SURVIVAL; DRUG UPTAKE; HUMAN; HYPOXIA; LIVER METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT PLANNING; TUMOR BIOPSY;

EID: 68149129637     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2009.n.013     Document Type: Review

References (115)

1. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality Fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004; 22:4357-68.
2. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003; 44:1200-9.
3. Hany TF, Steinert HC, Goerres GW, et al. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002; 225:575-81.
4. Park IJ, Kim HC, Yu CS, et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 2006; 32:941-7.
5. Cohade C, Osman M, Leal J, et al. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003; 44:1797-803.
6. Esteves FP, Schuster DM, Halkar RK. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med 2006; 36:169-81.
7. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000; 43:759-67.
8. Gutman F, Alberini J, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol 2005; 185:495-500.
9. Kamel EM, Thumshirn M, Truninger K, et al. Significance of incidental 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004; 45:1804-10.
10. Yasuda S, Fujii H, Nakahara T, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med 2001; 42:989-92.
11. Mainenti PP, Salvatore B, D'Antonio D, et al. PET/CT colonography in patients with colorectal polyps: a feasibility study. Eur J Nucl Med Mol Imaging 2007; 34:1594-603.
12. Gollub MJ, Akhurst T, Markowitz AJ, et al. Combined CT colonography and 18FFDG PET of colon polyps:potential technique for selective detection of cancer and precancerous lesions. AJR Am J Roentgenol 2007; 188:130-8.
13. Mercury study group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 2006; 333:779-84.
14. Bipat S, Glas AS, Slors FJM, et al. Rectal cancer:Local staging and assessment of lymph node involvement with endoluminal US, CT and MR imaging-a metaanalysis. Radiology 2004; 232:773-83.
15. Kantorova I, Lipska L, Belohlavek O, et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003; 44:1784-8.
16. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206:755-60.
17. Furukawa H, Ikuma H, Seki A, et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 2006; 55:1007-11.
18. Gearhart SL, Frassica D, Rosen R, et al. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 2006; 13:397-404.
19. Squillaci E, Manenti G, Mancino S, et al. Staging of colon cancer: whole body MRI vs whole body PET-CT-initial clinical experience. Abdom Imaging 2008; 33:676-88.
20. Veit P, Kuhle C, Beyer T, et al. Whole body positron emission tomography/computed tomography (PET/CT) tumour staging with integrated PET/CT colonography: technical feasibility and first experiences in patients with colorectal cancer. Gut 2006; 55:68-73.
21. Veit-Haibach P, Kuehle CA, Beyer T, et al. Diagnostic accuracy of colorectal cancer staging with whole body PET/CT colonography. JAMA 2006; 296:2590-600.
22. Kinner S, Antoch G, Bockish A, et al. Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging. Abdom Imaging 2007; 32:606-12.
23. Park IJ, Kim HC, Yu CS, et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 2006; 32:941-7.
24. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42:1S-93S.
25. Rodriguez-Moranta F, Salo J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006; 24:386-93.
26. Flanagan FL, Dehdashti F, Ogunbiyi OA, et al. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998; 227:319-23.
27. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177-89.
28. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997; 38:1196-201.
29. Valk PE, Abella-Columna E, Haseman MK, et al. Wholebody PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134:503-11.
30. Kostakoglu L, Agress H, Goldsmith S. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003; 23:315-40.
31. Delbeke D, Martin WH. PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 2004; 32:209-23.
32. Long-Bang C, Jin-Long T, Hai-Zhu S, et al. 18F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol 2007; 13:5025-9.
33. Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis meta-analysis. Radiology 2005; 237:123-31.
34. Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996; 131:703-7.
35. Selzner M, Hany TF, Wildbrett P, et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240:1027-34; discussion, 1035-6.
36. Truant S, Huglo D, Hebbar M, et al. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005; 92:362-9.
37. Wiering B, Krabbe PF, Jager GJ, et al. The impact of fluor-18- deoxyglucosepositron emission tomography in the management of colorectal liver metastases. Cancer 2005; 104:2658-70.
38. Ito K, Kato T, Tadokoro M, et al. Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology 1992; 182:549-52.
39. Herbertson RA, Lee ST, Tebbutt N, et al. The expanding role of PET technology in the management of patients with colorectal cancer. Ann Oncol 2007; 18:1774-81.
40. Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol 2006; 79:32-6.
41. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354:496-507.
42. De Gues-Oei LF, Van Laarhoven HW, Visser EP. Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer. Ann Oncol 2008; 19:348-52.
43. de Geus-Oei LF, Wiering B, Krabbe PF, et al. FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. Ann Oncol 2006; 17:1650-5.
44. Metser U. 18F-FDG PET in evaluating patients treated for metastatic colorectal cancer: can we predict prognosis? J Nucl Med 2004; 45:1428-30.
45. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol 1996; 14:700-8.
46. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, et al. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. J Nucl Med 2004; 45:1480-7.
47. Konski A, Hoffman J, Sigurdson E, et al. Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. Semin Oncol 2005; 32:S63-7.
48. Capirci C, Rampin L, Erba PA, et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 2007; 34:1583-93.
49. Kalff V, Duong C, Drummond EG, et al. Findings on 18F-FDG PET scans after neo-adjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med 2006; 47:14-22.
50. Capirci C, Rubello D, Chierichetti F, et al. Long term prognostic value of 18FFDG PET in patients with locally advanced rectal cancer previously treated with neoadjuvant chemoradiotherapy. AJR Am J Roentgenol 2006; 187:W202-8.
51. Kristiansen C, Loft A, Berthelsen AK, et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum 2008; 51:21-5.
52. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med 2006; 47:1059-66.
53. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35:1773-82.
54. Wieder HA, Brucher BL, Zimmermann F, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22:900-8.
55. Wieder HA, Ott K, Lordick F, et al. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinoma of the esophagagastric junction. Eur J Nucl Med Mol Imaging 2007; 34:1925-32.
56. Barker DW, Zagoria RJ, Morton KA, et al. Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT. AJR Am J Roentgenol 2005; 184:1096-102.
57. Bienert M, McCook B, Carr B, et al. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. Eur J Nucl Med Mol Imaging 2005; 32:778-87.
58. Wong CO, Salem R, Raman S, et al. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med 2002; 29:815-20.
59. Gondi V, Bradley K, Minesh M, et al. Impact of hybrid fluorodeoxyglucose positron emission tomography/computed tomography on radiotherapy planning in esophageal and non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2007; 67:187-95.
60. Grills IS, Yan D, Black QC, et al. Clinical implications of defining gross tumor volume with combination of 18FDG-positron emission tomography in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2007; 67:187-95.
61. Ashamalla H, Rafla S, Parikh K, et al. The contribution of integrated PET/CT on the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 2005; 63:1016-23.
62. Ashamalla H, Guirgius A, Bieniek E, et al. The impact of positron emission tomography/computed tomography in edge delineation of gross tumour volume for head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 68:388-95.
63. Ciernik IF, Huser M, Burger C, et al. Automated functional image guided radiatiob treatment planning for rectal cancer. Int J Radiat Oncol Biol Phys 2005; 62:893-900.
64. Bassi MC, Turri L, Sacchetti G, et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2008; 70:1423-6.
65. Groves AM, Win T, Ben Haim S, et al. Non-[18F]FDG PET in clinical oncology. Lancet Oncol 2007; 8:822-30.
66. Buck AK, Hetzel M, Schirrmeister H, et al. Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging 2005; 32:525-33.
67. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003; 52:1602-6.
68. Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [18F]3'-flurothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007; 34:878-83.
69. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia initiated angiogenesis. Nature 1992; 359:843-5.
70. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46:253-60.
71. Hicks RJ, Rischkin D, Fisher R, et al. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating an hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005; 32:1384-91.
72. Loi S, Ngan SY, Hicks RJ, et al. Oxaliplatin combined with infusional 5-FU and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. Br J Cancer 2005; 92:655-61.
73. Laking GR, West C, Buckley DL, et al. Imaging vascular physiology to monitor cancer treatment. Crit Rev Oncol Hematol 2006; 58:95-113.
74. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of FDG-PET in oncology. J Nucl Med 2008; 49:480-508.
75. Tuncbilek N, Karakas HM, Altaner S. Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas. Abdom Imaging 2004; 29:166-72.
76. Tateishi U, Kusumoto M, Nishihara H, et al. Contrast enhanced dynamic computed tomography for the evaluation of angiogenesis in patients with lung carcinoma. Cancer 2002; 95:835-42.
77. Wang JH, Min PQ, Wang PJ, et al. Dynamic CT evaluation of tumor vascularity in renal cell carcinoma. AJR Am J Roentgenol 2006; 186:1423-30.
78. Goh V, Halligan S, Daley F, et al. Quantitative assessment of colorectal tumor vascularity using MDCT: do tumor perfusion measurements reflect angiogenesis? Radiology, in press.
79. Atkin G, Taylor NJ, Daley FM, et al. Dynamic contrast enhanced magnetic resonance imaging is a poor measure of colorectal cancer angiogenesis. Br J Surg 2006; 93:992-1000.
80. Li ZP, Meng QF, Sun CH, et al. Tumor angiogenesis and dynamic CT in colorectal carcinoma: radiologic-pathologic correlation. World J Gastroenterol 2005; 11:1287-91.
81. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7.
82. Meijerink MR, Van Cruijsen H, Hoekman K, et al. The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients. Eur Radiol 2007; 17:1700-13.
83. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21:3955-64.
84. Koukourakis MI, Mavanis I, Kouklakis G, et al. Early antivascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol 2007; 30:315-8.
85. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of anti-angiogenic and antivascular therapies in early stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005; 92:1599-610.
86. Evelhoch JL, Garwood M, Vigneron D, et al. Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res 2005; 65:7041-4.
87. Sahani D, Kalva SP, Hamberg LM, et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 2005; 234:785-92.
88. Bellomi M, Petralia G, Sonzogni A, et al. CT perfusion for the monitoring of neoadjuvant chemoradiation therapy in rectal carcinoma. Radiology 2007; 244:486-93.
89. George ML, Dzik-Jurasz AS, Padhani AR, et al. Non invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 2001; 88:1628-36.
90. DeVries AF, Griebel J, Kremser C, et al. Tumor microcirculation evaluated by dynamic contrast enhanced magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 2001; 61:2513-6.
91. Goh V, Padhani AR, Rasheed S. Imaging colorectal cancer angiogenesis. Lancet Oncol 2007; 8:245-55.
92. Goh V, Halligan S, Taylor SA, et al. Differentiating between diverticulitis and colorectal cancer: quantitative CT perfusion measurements versus morphologic criteria initial experience. Radiology 2007; 242:456-62.
93. Miles KA, Leggett DA, Kelley BB, et al. In vivo assessment of neovascularisation of liver metastases using perfusion CT. Br J Radiol 1998; 71:276-81.
94. Leggett DA, Kelley BB, Bunce IH, et al. Colorectal cancer: diagnostic potential of CT measurements of hepatic perfusion and implications for contrast enhancement protocols. Radiology 1997; 205:716-20.
95. Goh V, Halligan S, Wellsted DM, et al. Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. Eur Radiol 2009; 19:79-89.
96. Muller-Schimpfle M, Brix G, Layer G, et al. Recurrent rectal cancer: diagnosis with dynamic MR imaging. Radiology 1993; 189:881-9.
97. Dicle O, Obuz F, Cakmakci H. Differentiation of recurrent rectal cancer and scarring with dynamic MR imaging. Br J Radiol 1999; 72:1155-9.
98. Torricelli P, Pecchi A, Luppi G, et al. Gadolinium-enhanced MRI with dynamic evaluation in diagnosing the local recurrence of rectal cancer. Abdom Imaging 2003; 28:19-27.
99. Rudisch A, Kremser C, Judmaier W, et al. Dynamic contrast enhanced magnetic resonance imaging: a non-invasive method to evaluate significant differences between malignant and normal tissue. Eur J Radiol 2005; 53:514-9.
100. Stejskal EO, Tanner JE. Spin diffusion measurements: spin echo in the presence of a time dependent field gradient. J Chem Phys 1965; 42:288-92.
101. DeVries AF. Kremser C, Hein PA, et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 2003; 56:958-65.
102. Dzik-Jurasz A, Domenig C, George M, et al. Diffusion MRI for prediction of response to chemoradiation. Lancet 2002; 360:307-8.
103. Koh DM, Scurr E, Collins DJ, et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007; 188:1001-8.
104. Cui Y, Zhang XP, Sun YS, et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008; 248:894-900.
105. Hosonuma T, Tozaki M, Ichiba N, et al. Clinical usefulness of diffusion-weighted imaging using low and high b-values to detect rectal cancer. Magn Reson Med Sci 2006; 5:173-7.
106. Ichikawa T, Erturk SM, Motosugi U, et al. High B-value diffusion weighted MRI in colorectal cancer. AJR Am J Roentgenol 2006; 187:181-4.
107. Koh DM, Brown G, Riddell AM, et al. Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol 2008; 18:903-10.
108. Koh DM, Brown G, Temple L, et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings initial observations. Radiology 2004; 231:91-9.
109. Harisinghani M, Barentsz J, Hahn PF, et al. Non-invasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491-9.
110. Rockall AG, Sohaib SA, Harisinghani M, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005; 23:2813-21.
111. Harada T, Tanigawa N, Matsuka M, et al. Evaluation of lymph node metastases of breast cancer using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. Eur J Radiol 2007; 63:401-7.
112. Lin G, Ho KC, Wang JJ, et al. Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging 2008; 28:128-35.
113. Hasegawa L, Boiselle PM, Kuwabara K, et al. Mediastinal lymph nodes in patients with non-small cell lung cancer: preliminary experience with diffusionweighted MR imaging. J Thorac Imaging 2008; 23:157-61.
114. Nomori H, Mori T, Ikeda K, et al. Diffusion weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg 2008; 135:816-22.
115. Taylor NJ, Baddeley H, Goodchild KA, et al. BOLD-MRI of human tumor oxygenation during carbogen breathing. J Magn Reson Imaging 2001; 14:156-63.